Divestments
Fertin Pharma
Deliver active ingredients effectively and pleasantly.
Fertin Pharma develops and manufactures pharmaceutical and nutraceutical products for leading global companies to support healthier living.
- Sector
Healthcare
- Country
Denmark
- Fund
EQT Mid Market Europe
- Entry
2017
- Exit
2021
Responsible Advisor
Rikke Kjær Nielsen
Website
About Fertin Pharma
Fertin Pharma helps customers create effective, convenient and pleasant high-quality products based on their innovative oral and intra-oral delivery systems including compressed and extruded gum, lozenges, ZapLiq® and pouch powder.
Fertin’s product portfolio has a broad variety of current and possible application areas including Nicotine Replacement Therapy, oral care, gastrointestinal, pain and allergy management, cough and cold and much more.
Fertin supports brand owners and retailers through partners in developing new and innovative products. As an example, its unique combination of more than 100 years of confectionary heritage, profound nicotine knowledge and pharma manufacturing capabilities has made the company the largest independent manufacture of medicated chewing gum in the world.
The company employs more than 700 people across R&D centers and manufacturing facilities in Canada, India and Denmark.
EQT acquired Fertin Pharma in January 2017 and thus entered a partnership with the Bagger-Sørensen family, who still holds a 30% interest in the company.
Do You Want to Know More?
We are eager to explore how we can achieve great things together.